---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059496"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:59:12.645111+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio Q1 2024 net loss $28.0M; on track for lupus nephritis trial and ADI-270 IND

## Summary
- Net loss of $28.0M ($0.35 per share) vs $30.9M ($0.72 per share) in Q1 2023.
- Cash and equivalents $247.6M as of March 31, 2024; expected runway into H2 2026.
- On track to initiate Phase 1 of ADI-001 in lupus nephritis in Q2 2024; data expected Q4 2024 or Q1 2025.
- Preclinical data for ADI-270 presented at ASGCT; IND for renal cell carcinoma planned Q2 2024.
- Enrolling MCL patients in ADI-001 GLEAN study; clinical update with 6-month data expected H2 2024.

## SEC filing metadata
- accession: 0000950170-24-059496
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017024059496/0000950170-24-059496-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017024059496/acet-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059496
- JSON: https://secwatch.observer/filing/0000950170-24-059496.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059496.txt

## Key facts
- Earnings Releases
  Adicet Bio, Inc. reported first quarter ended March 31, 2024 results: net income net loss of $28.0 million, EPS $0.35 per basic and diluted share.
  - Period: first quarter ended March 31, 2024
  - Net income: net loss of $28.0 million
  - EPS: $0.35 per basic and diluted share
  - Result: reported results
  source text: Net loss for the three months ended March 31, 2024 was $28.0 million, or a net loss of $0.35 per basic and diluted share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720580/000095017024059496/0000950170-24-059496-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.